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The branched chain amino acids (BCAAs) are three essential amino acids: 
valine, leucine, and isoleucine. Adipose tissue has high rates of BCAA degradation 
and this has been shown to fuel normal function. Recent literature highlights cross-
talk between BCAAs, lipid metabolism, and mitochondrial dysfunction. The objective 
of this thesis is to determine the impact of BCAA supplementation on adipose 
development, morphology, and various aspects of energy metabolism including 
BCAA degradation and lipolysis.  
C57-BL6N mice were reared on either low-fat (LF), LF with 150% BCAAs 
(LB), high-fat (HF), or HF with 150% BCAAs (HB) diets for 12-34 weeks. Adipose 
tissue morphology and energetics were determined.  
  
Results demonstrated that BCAA supplementation reduced lipid storage in 
visceral adipose depots, lowered circulating leptin, and reduced lipid accumulation in 
brown adipose tissue. BCAA supplementation also induced lipolysis, which raised 
circulating fatty acids. These results could have implications in the treatment and 
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Chapter 1: Introduction 
 
The branched chain amino acids (BCAAs) are three essential amino acids, 
Valine, Leucine, and Isoleucine, and are well known for their regulatory effects on 
protein, glucose, and lipid homeostasis in a variety of tissues. The BCAAs and their 
degradation are very responsive to the actions of insulin, and as such, defects in BCAA 
metabolism are central to the etiology of insulin resistant states including obesity, type 
II diabetes mellitus (T2DM), and non-alcoholic fatty liver disease (NAFLD). 
Additionally, degradation products of BCAA metabolism are anaplerotic substrates for 
the mitochondrial tri-carboxylic acid (TCA) cycle. Therefore, BCAAs can modulate 
mitochondrial function by impacting the TCA cycle activity and its intermediates. 
Similarly, the BCAAs also have potent signaling functions through their interactions 
with several molecular regulators of mitochondrial function (Neinast et al., 2019; Ye 
et al., 2020). Taken together, impairments in both BCAA catabolism and mitochondrial 
function are evident in insulin resistant tissues, and are characteristic features of 
obesity, NAFLD, and T2DM (Bjørndal et al., 2011; Gannon et al., 2018).  Therefore, 
understanding the link between BCAAs, their degradation networks, and mitochondrial 
dysfunction at a tissue and cellular level is an area of significant interest for the study 
and management of metabolic diseases. 
 The BCAAs are major metabolic substrates for adipose tissue, which plays a 
crucial role in whole body BCAA degradation and clearance. Adipose tissue does this 
by using BCAAs as substrates for metabolite synthesis, energy, and heat production. 
For example, BCAAs are catabolized and utilized by maturing white adipose tissue 
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(WAT) to form new lipids (Estrada-Alcalde, Isabela et al., 2016). In murine brown 
adipose tissue (BAT) during cold challenges, mitochondria extensively utilize BCAAs 
as metabolic substrates for non-shivering thermogenesis (Yoneshiro et al., 2019). The 
utilization of BCAAs in WAT and BAT promote effective clearance of circulating 
BCAAs from the system. Defects in the ability of adipose tissue to efficiently 
catabolize BCAAs during the progressive severity of insulin resistance is thought to 
contribute to the increase of circulating levels of BCAAs, which is robustly correlated 
to indices of insulin resistance and is used as a clinical indicator for the development 
of insulin resistance (Nie et al., 2018). 
BCAAs have also been shown to impact adipocytes through their ability to 
modulate adipocyte differentiation, mechanisms of lipid storage, and rates of lipolysis. 
In support of this, BCAA deprivation resulted in blunted adipocyte differentiation 
(Estrada-Alcalde, Isabela et al., 2016). Furthermore in growing swine, excessive 
BCAAs lead to an increase in the rate of adipose lipolysis (Heng et al., 2020). The 
multiple interactions between the BCAAs and various facets of adipose tissue function 
clearly illustrate the significant role of the BCAAs in maintaining the metabolic health 
of the adipose tissue.  
Based on the above observations, we hypothesized that chronic, dietary 
supplementation of BCAAs will impact adipocyte function in WAT and BAT. We 
further hypothesized that this BCAA mediated induction of WAT and BAT 
function will be blunted during whole body insulin resistance.  
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 We tested our hypothesis in mice reared on a low-fat or high-fat diets 
supplemented with either 150% excess or normal levels of BCAAs. The following were 
the objectives of this study: 
1) To determine the impact of BCAAs on adipose tissue development and morphology 
during normal and insulin resistant states. 
2) To determine the impact of BCAA supplementation on BCAA degradation and 
mitochondrial function in WAT and BAT during normal and insulin resistant states. 
3) To determine the impact of BCAAs on rates of lipolysis in WAT during normal and 
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Chapter 2: Literature Review 
 
Branched Chain Amino Acids and Insulin Action 
Valine, leucine, and iso-leucine are three essential amino acids that are referred 
to as the branched chain amino acids (BCAAs, Figure 1). Although they cannot be 
synthesized by mammals and are solely provided by the diet, they make up 
approximately 35% of all essential amino acids in mammalian systems (Neinast et al., 
2019). These metabolites are extremely sensitive to the actions of insulin and are 
intimately linked to the onset of insulin resistance. High circulating BCAAs are a 
clinical sign which is strongly associated with multiple indices of insulin resistance 
(Yoon, 2016; Zhao et al., 2016), and are evident during obesity, T2DM, and NAFLD. 
Under normal physiological conditions, BCAAs are utilized for protein synthesis or 
oxidized for energy (Neinast et al., 2019). This oxidation that occurs in the tissues is 
regulated by insulin, and is impaired when insulin resistance is present. The 
dysfunction of these catabolic pathways is thought to be the contributing factor for 
increased circulating levels during insulin resistance (Wang et al., 2019).  
 
Figure 1: Chemical structures of the branched chain amino acids Valine, Leucine, and 
Isoleucine, Source: (Proteomics, n.d.) 
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Tissue BCAA Degradation Pathways 
 
 Muscle is the dominant tissue that catabolizes BCAAs. Adipose, liver, kidney, 
heart, and brain tissue are other contributors to BCAA degradation (Holeček, 2018). 
The first step in the catabolism of BCAAs is catalyzed by the enzyme branched-chain-
amino-acid aminotransferase (BCAT). In the cytosol, BCAT trans-aminates the 
BCAAs. Alpha-ketoglutarate is the amino group acceptor and this reaction forms the 
corresponding branched chain keto-acids (BCKAs) and glutamate as products. The 
second step of BCAA catabolism occurs within the inner membrane of the 
mitochondria. The activated branched chain keto acid dehydrogenase (BCKDH) 
complex releases CO2, reduces NAD+ to NADH, adds a Co-A molecule to the 
branched chain keto acid, and this can then be used to replenish TCA cycle 
intermediates  and form ketones (Neinast et al., 2019). Leucine degradation yields 
ketogenic products, valine serves as gluconeogenic substrates, and isoleucine can 
produce both ketogenic and gluconeogenic products (Figure 2). 
 
Figure 2: Specific degradation pathways for each of the BCAAs. Source: (Chuang et 
al., 2006) 
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  Due to the responsiveness of the BCAA degradation networks to insulin, it is 
clear that that insulin resistance would impair the efficiency of this pathway leading 
to an accumulation of BCAA degradation substrates and intermediates. Several 
studies have linked obesity and high lipid consumption with decreased expression of 
the BCAA catabolism enzymes BCAT and BCKDH (Estrada-Alcalde et al., 2017; 
Lackey et al., 2013), highlighting the BCAA degradation impairment that occurs 
during obesity. Additionally, increasing expression of these enzymes is one of the 
effects of a popular drug class Thiazolidinediones (TZDs). These drugs are prescribed 
to improve insulin sensitivity. TZDs mechanism of action is they activate peroxisome 
proliferator activated receptor-gamma (PPARγ), which regulates the gene expression 
of proteins associated with glucose, lipid, and protein homeostasis (Eggleton & Jialal, 
2021). Blanchard et al. provides evidence that activation of PPARγ rescues BCAA 
oxidation levels and contributes to reducing circulating BCAA levels in an obese 
mouse model system (2018).  
Normal Adipose Tissue Function and Physiology in White and Brown Adipose Tissue 
Homeostatic regulation of energy via the utilization and supplementation of 
circulating metabolites is the goal of nutrient metabolism. Many tissues, such as 
skeletal and cardiac muscle, liver, and adipose use specialized mechanisms and 
processes to achieve this goal. Adipose tissue, the focus of this thesis, both stores and 
supplies energy to the body in the form of lipids.  
Adipose tissue is found in localized areas of the body, referred to as adipose 
depots. Preferential storage of lipids in these depots can be used to estimate metabolic 
health and the propensity to develop diseases in future (Haczeyni et al., 2018). Two 
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types of adipose depots determine this: visceral and subcutaneous. Visceral depots are 
found within the abdominal cavity and in close proximity to the gastrointestinal tract 
and subcutaneous depots are localized under the skin. Comparing the size of the 
visceral depots to subcutaneous depots can serve as predictors of overall metabolic 
health. Large visceral depots indicate a metabolically unhealthy individual with a 
higher risk of developing insulin resistance and heart disease (Klein, 2004). The 
mechanisms by which lipids are preferentially stored in visceral or subcutaneous depots 
remain unknown.  
 
 
Figure 3: Various murine adipose depots. Source: (Bagchi & MacDougald, 2019) 
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Adipose tissue is comprised primarily of adipose cells (adipocytes), but it is 
important to note that other cell types contribute to adipose tissue development and 
function as well. Among these cells are: macrophages, lymphocytes, vascular cells, and 
pre-adipocytes (Ouchi et al., 2011). All adipocytes have the general function of lipid 
storage and mobilization, but the end goal and physical characteristics can differ. The 
two general types of adipose tissue, brown (BAT) and white (WAT), differ in both 
physical characteristics and metabolic functions.  
WAT is the most abundant adipocyte type found in the body. 90% of WAT cell  
volume is comprised of a unilocular lipid droplet (Saely et al., 2012). The lipid droplet 
is considered an organelle and protects the cell and peripheral tissues from lipotoxicity 
by storing excess lipids within it (Luo & Liu, 2016). These cells are spherical and their 
size is dependent on the amount of lipids store. As excess nutrients are taken up, white 
adipocytes expand to accommodate more lipid storage. During fasting or energy 
deficiency, when lipid stores are utilized, the cells shrink moderately. This plasticity 
during feeding and fasting is one of the specialized mechanisms by which WAT 
maintains energy homeostasis in the body.  
 
 
Figure 4: Histological examples of white (A), beige (B), and brown (C) adipose tissue. 
Source: (Keipert & Jastroch, 2014) 
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Brown adipocytes are highly specialized cells whose main role is 
thermogenesis. These adipocytes form many, small intracellular lipid droplets and have 
numerous mitochondria, which give the tissue its characteristic brown color. 
Mitochondria in brown adipocytes are specialized for non-shivering thermogenesis and 
can defer the end product of oxidative phosphorylation from energy to heat production 
during cold environmental conditions. This is achieved by the use of uncoupling 
protein-1 (UCP-1), found at the end of the electron transport chain. Activation of this 
protein allows for the oxidation of fatty acids to generate heat (Saely et al., 2012). The 
amount of BAT in an organism is very little compared to WAT, and depends on the 
ambient environment of the organism. Animals living in a cold climate produce more 
BAT, as thermogenesis is an important part of their survival. Animals in warm climates 
have BAT that resembles WAT, with large lipid droplets and adipocytes that cater more 
towards lipid storage.  
A recent advancement in the understanding of adipose has revealed a third type 
of tissue called beige adipose tissue. As the name implies, beige tissue is a hybrid of 
white and brown. During cold challenges, “beigeing” can occur, where this tissue 
resembles BAT and even expresses UCP-1, the BAT specific thermogenesis protein. 
However, during normal conditions it looks characteristically similar to WAT. Beige 
tissue appears to only be found in certain adipose depots, such as the inguinal and 
scapular areas of the body (Sanchez-Gurmaches et al., 2016). It is a current area of 
study as to where these cells originate. If they have BAT origins that would explain the 
similarities. This topic, however, is more complex than it seems. Research is being 
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conducted to further understand this tissue, its origins, and how it can be utilized as a 
potential target area for the treatment of obesity and type II diabetes.  
Adipose as a Endocrine Organ 
 
Originally thought of simply as a storage organ, adipose tissue has been 
revealed to be an important endocrine organ releasing factors that both prevent and 
progress metabolic diseases. These adipose specific endocrine factors are referred to as 
adipokines. Most adipokines are pro-inflammatory and have been linked to the 
advancement of systemic metabolic dysfunction beginning with adipose tissue (Ouchi 
et al., 2011). One of these adipokines is leptin, an appetite hormone linked to obesity 
and insulin resistance. Leptin is the hormone that communicates the levels of energy 
storage in adipose tissue to the hypothalamus of the brain. High leptin release serves as 
a signal that energy stores are sufficient and the system can reduce feeding. During 
times of starvation or fasting, leptin levels fall and allow normal feeding and the 
replenishment of lipid stores. Clinical deficiency of leptin causes hyperphagia 
(overeating) and obesity, and is precisely the mechanism behind the ob/ob mouse which 
is popularly used as a model of obesity. During normal obesity, leptin levels are 
chronically high in response to excess nutrient uptake. Eventually, leptin resistance will 
develop and will no longer efficiently signal the reduction of feed intake (Kelesidis et 
al., 2010).  
It is recognized that metabolic dysfunction is progressed by chronic 
inflammatory states. Adipose releases a number of inflammatory adipokines, including 
tumor necrosis factor (TNF) and interleukin-6 (IL6). When adipocytes expand to a 
critical size, they release inflammatory adipokines and recruit macrophages, which 
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contribute to this inflammatory response by producing TNF. Obese individuals with 
high adiposity present higher levels of TNF and IL-6 and these levels are reduced with 
weight loss (Ouchi et al., 2011).  
An anti-inflammatory and insulin sensitizing cytokine produced by adipose is 
adiponectin. It impacts liver, muscle, adipose, and vascular tissue and is a potent target 
for insulin resistance and obesity treatment because of its beneficial impacts. 
Adiponectin signaling pathways positively impact insulin signaling and fatty acid 
oxidation. In ob/ob mice, over expression of adiponectin not only rescued dietary 
induced insulin resistance, but also reduced inflammation by decreasing macrophage 
presence and TNF levels in the adipose tissue (Kim et al., 2007). It has also been 
reported that the 3T3L1 pre-adipocyte cell line releases high amounts of adiponectin, 
indicating a positive correlation between adipocyte differentiation and adiponectin 
(Achari & Jain, 2017). 
Factors Influencing Adipose Expansion and Differentiation 
Adipose expansion is the process of increasing the size of adipose tissue. This 
is achieved either by increasing the size of the existing adipocytes (hypertrophy) or 
increasing the number of new adipocytes (hyperplasia). Initially, as more excess lipids 
are taken up or formed, adipocytes will expand the intracellular lipid droplets to 
accommodate. However, after the cells reach critical size and can no longer expand, 
they begin releasing inflammatory cytokines like interleukin-6 (IL-6) and tumor 
necrosis factor alpha (TNF-alpha) (Choe et al., 2016). Other hormone profiles are 
altered during hypertrophy, such as decreased adiponectin and increased leptin release. 
As adiponectin and leptin are hormones related to insulin sensitivity, hypertrophic 
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adipocytes have a higher propensity to develop insulin resistance. Also released are 
differentiation cytokines that signal for pre-adipocytes to begin differentiation and 
maturation.  
Adipocyte Differentiation 
 Each adipose depot has its respective pool of pre-adipocyte cells present. When 
adipocytes form from mesenchymal precursor cells, they undergo differentiation. 
Differentiation is the process by which the cell changes its gene expression to display 
the adipocyte phenotype. This process is regulated by transcription factors such as 
C/EBPα and PPARγ, which express early in the differentiation process and maintain 
expression through a positive feedback loop to preserve the adipocyte phenotype 
(Siersbaek et al., 2010).  
 It was previously accepted that due to the distinct differences in brown and 
white adipocytes, they would have different cellular origins. This, however, has been 
proven to be more complex. Studies have shown that there is not a single origin for 
BAT or WAT, but multiple precursor cells exist for white and brown tissue (Sanchez-
Gurmaches et al., 2016). There is still much to be studied and understood in the area of 
adipocyte differentiation, cell origin, and the process and determining factors for 
adipocyte commitment.  
Adipose Tissue and Lipid Metabolism 
In any metabolic process there are two pathways: synthesis (anabolism) and 
degradation (catabolism). In adipocyte lipid metabolism, the anabolic and catabolic 
pathways are lipogenesis and lipolysis, respectively. Lipid sources include endogenous 
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de novo lipids and dietary lipids from food intake. De novo lipids can be synthesized 
using acetyl co-A derived from glycolysis or from fatty acid oxidation. Lipogenesis is 
highly regulated by many factors including hormones, gene expression, and nutrition 
(Kersten, 2001).  These newly formed lipids are stored in the lipid droplets of the cell, 
which protect the adipocyte from lipo-toxicity. The lipogenesis pathway is favored 
during times of nutrient intake and abundance. Conversely, during fasting or starvation 
fatty acids are released from the lipid droplets to provide energy to peripheral tissues. 
This process is lipolysis (Figure 5). The adipocyte contains several lipases that cleave 
fatty acids from the glycerol back bone. This process converts a triglyceride to a 
diacylglycerol, and further to a monoacylglycerol. The fatty acids and glycerol released 
by lipolysis are utilized by the adipocyte or transported through the blood to provide 
energy to other tissues and organs.  
 
Figure 5: Overview of lipid metabolism in adipocytes. Source: (Sethi, 2007) 
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Evidence of BCAAs and Adipose Tissue Expansion and Differentiation 
 
 Adipocyte differentiation is fueled by BCAA catabolism. Green, et al. reports 
30% of the acetyl Co-A pool used in lipogenesis is derived from BCAA catabolism 
(Green et al., 2016). Estrada-Alcade, et al. demonstrated that BCAA deprivation 
inhibits cell differentiation and lipid accumulation in maturing adipocytes while BCAA 
supplemetation significantly increases lipid formation (Estrada-Alcalde, Isabela et al., 
2016). In the same study, using isotope tracers, incorporation of BCAAs into maturing 
adipocytes was quantified.  During the later stages of differentiation, there are 
significant increases in the incoportation of BCAA (especially Leucine) degradation 
products into lipid and protein synthesis.  
PPARγ , the differentiation transcprition factor that promotes expression of 
adipocyte characteristics, also increases BCAA degradation. PPARγ agonists are 
commonly used drugs to combat insulin resistance. One such drug, Rosiglitazone, 
when admistered to rats on a HF diet, restored down-regulated BCAA degradation 
enzymes and lowered circulating BCAA levels (Blanchard et al., 2018). One question 
that requires more study is if increasing BCAA levels in a normal animal can “reverse” 
activate PPARγ, and possibly induce adipocyte differentiation.  
Evidence of BCAAs and Adipose Tissue Lipolysis 
 
 The process of lipolysis has many molecular regulators such as hormones, 
cytokines, and enzymes. It is known that BCAAs stimulate mammalian target of 
rapamycin (mTOR), a kinase that is involved in numerous homeostatic and metabolic 
networks (Yoon, 2016). In adipose, mTOR activation increases fatty acid synthesis, 
adipocyte differentiation, and lipogenesis (Soliman, 2011). More recently, the impact 
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of mTOR activity on lipolysis has been discussed. Soliman (2010) demonstrated that 
treatment of 3T3-L1 adipocytes with rapamycin, a mTOR inhibitor, increased lipolysis. 
Therefore, these results demonstrate that mTOR activation inhibits lipolysis. The 
conundrum, however, is that although BCAAs have been shown to activate mTOR, 
which inhibits lipolysis, BCAAs have also been shown to increase lipolysis themselves.  
Heng et al. (2020) has shown increased levels of lipolysis and higher expression 
of lipolytic proteins when weanling piglets were fed a high-BCAA diet. Interestingly, 
these same changes in lipid metabolism were also seen in piglets fed low-BCAAs diets 
in the same study. The mechanism by which BCAAs increase lipolysis is described by 
this paper as BCAAs modifying m6A RNA methylation. In a high-fat diet condition, 
mice supplemented with BCAAs showed increased lipolytic rates despite simultaneous 
treatment with insulin (Zhang et al., 2016). These studies provide evidence that BCAAs 
impact lipolysis, however a mechanism remains to be elucidated, as well as 
determining if this impact on lipolysis is beneficial or harmful for normal and insulin 
resistant physiology,  
Adipose Tissue, BCAA degradation, and Mitochondrial Function 
 
 The association between adipose tissue, BCAA degradation, and mitochondrial 
function in relation to metabolic diseases is a large area of study. Mitochondria play 
critical, adipocyte specific roles in adipose tissue functions (Figure 6) including 
adipocyte differentiation, lipid metabolism, thermogenesis, and insulin sensitivity. 
However, dysfunction of mitochondria during obesity and IR can impact the 
mitochondria’s ability to regulate and aid in these pathways that maintain normal 
adipocyte function. This can stem from an accumulation of reactive oxygen species 
  16 
(ROS) during chronic, mitochondrial oxidative stress (Lee et al., 2019), and 
accumulated ROS can further induce IR.   
 
 




As previously mentioned, BCAAs are susceptible to the actions of insulin and 
are also impacted during insulin resistant metabolic states, specifically the degradation 
of BCAAs. BCAA degradation products can also replenish the TCA cycle. Adipose 
tissue is recognized as an organ that is responsible for the catabolism of considerable 
amounts of BCAAs and is involved in the whole-body homeostatic regulation of 
circulating amino acids (Herman et al., 2010). Since BCAA metabolism occurs partly 
in the mitochondria and further fuels mitochondrial pathways, impairment of either 
BCAA catabolism or mitochondrial function will inevitably impact the other.  
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Chapter 3: Experimental Design and Methods 
Animals 
All animal protocols were approved by the University of Maryland Institutional 
Care and Use committee. Mice were housed at 22°C with a 12-h light-dark schedule, 
and given feed and water ad libitum. 6-8 week old C57-BL6N male mice (Jackson 
Laboratory) were kept on four specialized custom diets (Research Diets, Inc., see Table 
1) for 12-34 weeks: low-fat (LF, 10% fat, D12450J), low-fat supplemented with 
BCAAs (LB, 10% fat, 150% BCAAs, D19050804), high-fat (HF, 60% fat, D12492), 
and high-fat supplemented with BCAAs (HB, 55% fat, 150% BCAAs, D19121607). 
Cages were stocked with 3-5 mice each, and all mice within a cage were on the same 
custom diet. Body weights of each mouse and the feed intake of the cages were 
measured weekly. Mice were randomized into fed and fasted (~16 hours overnight) 
groups, euthanized under isoflurane anesthesia, and adipose and blood were collected. 
Part of the tissues were used fresh, fixed in formalin for histology, or flash frozen in 
liquid nitrogen and stored at -80°C for further analysis. Serum was isolated by 
centrifuging the clotted blood at 3,000rpm for 10 minutes and taking the supernatant. 
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Table 1 
Custom Mouse Diet Compositions 
 Low Fat (LF) Low Fat w/ 
BCAA (LB) 
High Fat (HF) High Fat w/ 
BCAA (HB) 
Product # D12450J D19050804 D12492 D19121607 
% kcal Protein 20 25 (150% 
BCAA) 
20 25 (150% 
BCAA) 
% kcal Carbohydrate 70 65 20 20 
% kcal Fat 10 10 60 55 
Ingredients grams kcal grams kcal grams kcal grams kcal 
Casein 200 800 200 800 200 800 200 800 
L-Cystine 3 12 3 12 3 12 3 12 
L-Isoleucine 0 0 11.46 46 0 0 11.46 46 
L-Leucine 0 0 23.97 96 0 0 23.97 96 
L-Valine 0 0 14.11 56 0 0 14.11 56 
Maltodextrin 10 125 500 125 500 125 500 125 500 
Corn Starch 506.2 2025 456.66 1827 0 0 0 0 
Sucrose 68.8 275 68.8 275 68.8 275 68.8 275 
Cellulose, BW200 50 0 50 0 50 0 50 0 
Soybean Oil 25 225 25 225 25 225 25 225 
Lard 20 180 20 180 245 2205 223 2007 
Mineral Mix S10026 10 0 10 0 10 0 10 0 
DiCalcium Phosphate 13 0 13 0 13 0 13 0 
Calcium Carbonate 5.5 0 5.5 0 5.5 0 5.5 0 
Potassium Citrate, 1 H20 16.5 0 16.5 0 16.5 0 16.5 0 
Vitamin Mix V10001 10 40 10 40 10 40 10 40 
Choline Bitartrate 2 0 2 0 2 0 2 0 
FD&C Yellow Dye #5 0.04 0 0.05 0 0 0 0.05 0 
FD&C Red Dye #40 0 0 0 0 0 0 0 0 
FD&C Blue Dye #1 0.01 0 0 0 0.05 0 0 0 
     
Totals 1055.5 4057 1055.5 4057 773.85 4057 801.39 4057 
kcal/g 3.85 3.85 5.24 5.06 
 
Note. Composition of the specialized diets on which mice were reared for up to 34 
weeks. Purchased from Research Diets, Inc. 
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In-Vitro Lipolysis Assay 
 As an index of adipose lipolysis, three in vitro lipolysis assays utilizing 
adipose tissue explants were performed. The first assay utilized mice on diets for 34 
(LF and LB) or 24 (HF and HB) weeks. The media consisted of Dulbecco’s modified 
eagle medium (DMEM, Sigma-Aldrich, D6046), 10µM isoproterenol (Caymen 
Chemicals), 5µM Triacsin-C (Caymen Chemicals), and 2% FA-free bovine serum 
albumin (BSA) (See Table 2 for media formulation per treatment). To stimulate the 
tissue, isoproterenol (ISP), a catecholamine that induces lipolysis by serving as a 
beta-adrenergic receptor agonist that increases levels of cAMP (Szymanski & Singh, 
2021), was added to the media. The addition of Triacsin-C was to prevent re-
esterification of released fatty acids. A 10mM stock of isoproterenol and 5mM stock 
of Triacsin C were made in DMSO and stored at -20°C. Media was made fresh before 
each experiment. 200µL of each media was added to a 96-well plate which was pre-
warmed at 37°C. Fresh perigonadal WAT was cut into ~50mg pieces and placed in 
the plate containing the pre-warmed media. The plate was pre-incubated for 1 hour at 
37°C and 5% CO2, then the adipose was transferred to new wells containing 200µL of 
fresh, identical media and incubated in the same conditions for another hour. The 
adipose tissue and media were stored separately at    -80°C for further analysis. 
 The second lipolysis assay used 12 week dietary treated animals and increasing 
concentrations of BCAAs. For this experiment, a custom media devoid of BCAAs was  
necessary so we could add the desired concentrations (Table 3). Media was premade 
with BCAA concentrations of 500µM and 1mM and stored at -20°C. On the day of the 
experiment, media was thawed and 200µL was added to a 96-well plate and pre-
  20 
warmed at 37°C. ~30mg tissue explants were added to a pre-cooled plate containing 
DPBS until all explants were cut and weighed. Then they were transferred to the pre-
warmed plate and pre-incubated for 2 hours at 37°C and 5% CO2. After pre-incubation, 
explants were moved to a new well containing 200µL of fresh, identical media and 
incubated again for 1 hour. To rinse excess BSA in the media from the explants, they 
were washed in DPBS before storing. Adipose and media were stored at -80°C for 
further analysis. 
For the final lipolysis assay, normal chow-fed male mice were used. The same 
custom media (Table 3) was used, but with BCAA concentrations of 50µM, 500µM, 
1mM, and 2.5mM. This media also was used with and without 2.5µM isoproterenol. 
Before the experiment, the media was thawed and divided into two aliquots per BCAA 
concentration. The appropriate amount of 10mM isoproterenol stock was added to one 
aliquot for a final concentration of 2.5µM isoproterenol. 200µL of each media was 
loaded into a 96-well plate and pre-warmed at 37°C. ~30mg of perigonadal WAT 
explants were cut and sliced on a chilled ceramic tile on ice using a scalpel. This was 
to maximize the surface area of the tissue in contact with the media. Then the slices 
were transferred to a chilled plate containing DPBS. Once all explants were cut, 
weighed, and sliced, they were transferred to their respective wells in the pre-warmed 
plate. Pre-incubation at 37°C and 5% CO2 occurred for 1 hr. The slices were carefully 
transferred to a new well containing 200µL of fresh, identical media and incubated for 
2 more hours. After incubation, the tissue was washed of excess BSA by washing with 
DPBS prior to storage. Media and tissue explants were stored at -80°C for further 
analysis. 










Lipolysis Assay Media composition by Treatment 
Treatment Media 
Basal DMEM with 2% BSA 
Isoproterenol (ISP) 
DMEM with 2% BSA, 
10µM ISP, and  
5µM Triacsin-C 
 
Note. Media compositions per treatment for lipolysis assay using mice on custom 














Custom Adipose Tissue Explant Media 
DPBS (Gibco, 14040-117) 368mL 
NEAAs (100x, Gibco 1140-050) 4mL 
EAAs (25x, see Table 4) 16mL 
L-Glutamine (200mM, Gibco 25030-081) 2mL 
MEM Vitamix (100x, Gibco 11120-052) 4mL 
FA-Free BSA (Thermo-Fisher) 8g 
BCAA Stock (Table 5) Varies 
 
Note. Recipe for 400mL of custom media for adipose tissue explants. After all 
ingredients except for the BCAA stock was added and dissolved, media was aliquoted 
for BCAA concentrations and the proper amount of BCAA stock was added (Table 5). 
Then the media was brought to a pH of 7.4 at 37°C, filtered, aliquoted, and stored at -
20°C. DPBS-Dulbecco’s phosphate-buffered saline, NEAA- non-essential amino 
acids, EAA- essential amino acids, MEM- minimum essential medium 
 
  23 
 
Table 4 
Non-Essential Amino Acid (NEAA) 25x Stock Composition 
Amino Acid Weight (g) 
Concentration 





L-Arginine (Fisher, BP373) 0.063 18.08 0.7232 
L-Cystine (Sigma, C7602) 0.006 1.24 0.0496 
L-Histidine (Sigma, H8125) 0.0209 4.985 0.1994 
L-Lysine (Sigma, L5626) 0.036 9.85 0.394 
L-Methionine (Sigma, M9625) 0.007 2.34 0.0936 
L-Phenylalanine (Sigma, P2126) 0.0165 4.99 0.1996 
L-Threonine (Sigma, T8625) 0.023 9.65 0.386 
L-Tryptophan (Sigma, T0254) 0.005 1.224 0.0489 
L-Tyrosine (Sigma, T3754) 0.018 4.967 0.1986 
 
Note. Recipe for 25x NEAA stock for custom adipose tissue explant media (Table 3). 
Amino acids were weighed and dissolved in 20mL of 0.1N HCl, and stirred at 65°C for 
approximately one hour or until completely dissolved.  The stock was aliquoted and 











BCAA Stock Composition 
BCAA Weight (mg) Concentration in 50mL 
L-Leucine 660.1 100.65mM 
L-Isoleucine 408 62.21mM 
L-Valine 586 100.2mM 
 
Note. BCAA stock solution used to make custom adipose explant incubation media. 
BCAAs were weighed, added to 50mL of 0.1N HCl, and stirred until dissolved. The 
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Analysis of Non-Esterified Fatty Acids (NEFA)  
 
 NEFA assay kits were purchased from Wako Diagnostics. A standard curve 
was constructed using 1, 0.75, 0.5, 0.25, 0.125, 0.0625, 0.031, and 0 mM of 0leic acid 
(Wako Diagnostics). 5µL of standard and sample (lipolysis assay media or serum) was 
loaded per well, then 200µL of Reagent A was added. The plate was incubated at 37°C 
for 5 minutes and read at a 550nM. Then 100µL of Reagent B was added to each well 
and incubated another 5 minutes at 37°C.  The plate was read again at 550nM. To obtain 
the final concentrations, the first reading absorbance values were subtracted from the 
second absorbance values. This corrected absorbance was used to construct the 
standard curve and determine the concentration of NEFA in the sample.  
Analysis of Glycerol in Lipolysis Incubation  Media 
 
 To measure free glycerol in the lipolysis assay media, glycerol reagent from 
Sigma-Aldrich was used. A standard curve was constructed using glycerol diluted in 
the base media used in the lipolysis assay (DMEM). 5µL of standard and sample were 
loaded into a 96-well plate, and 200 µL of glycerol reagent was added. The plate was 
incubated at 37°C for 5 minutes an read at 540nM. Using the constructed standard 
curve, the concentration of free glycerol in the sample was calculated.  
Western Blot Analysis of Adipose Tissue Proteins 
 
To extract protein from the adipose tissue, 200µL of cold 1x RIPA (Table 6) 
with protease and phosphatase inhibitors (Fisher Scientific) was added to a tube 
containing frozen adipose tissue (~100mg WAT, ~10mg BAT) and zirconium oxide 
beads. The tissue was lysed using a bead mill homogenizer (VWR) on speed 5 for 30 
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seconds, allowed to rest on ice for 30 seconds, and repeated twice more. Once 
homogenized, the lysate was incubated on ice for one hour. To separate the fat from 
the protein lysate, the samples were spun at 20,000g and 4°C for 30 minutes. 125µL of 
the protein lysate was then carefully removed from under the fat layer using a gel-
loading pipette tip. A BCA assay (Thermofisher) was used to determine the protein 
concentration. 
The protein was diluted to a concentration of 2µg/µL using water, and 
appropriate amounts of running buffer (4:1 Bolt 4x, Thermofisher Scientific, and ß-
mercaptoethanol, Sigma-Aldrich) were added to each sample. The samples were heated 
at 95°C for 5 minutes, aliquoted, and stored at -80°C  until use. Premade gels 
(Invitrogen) were used and the samples were run using a 1x SDS MES running buffer 
(Fisher Scientific). The gel was transferred to a PVDF membrane (Fisher Scientific), 
blocked in 5% milk and incubated in the primary antibody (1:1000 dilution in 3%BSA, 
0.02% sodium azide, 1x TBS Tween) overnight at 4°C. The following day, the 
membrane was incubated in the secondary antibody (1:10,000 dilution, in 5% milk and 
1x TBS Tween) for one hour at room temperature. The membrane was washed with 
1X TBS-Tween three times for five minutes each between each step from blocking to 
imaging. To image, Pico West Plus and Lumigen were used. Antibodies used: COXIV 
(Cell Signaling, #11967), Beta-Actin (Cell-Signaling, #3700), OXPHOS antibody 













Recipe for 1x RIPA Lysis Buffer 
25mM Tris (pH 8.0) 1.51g (in 400mL of diH2O) 
150mM NaCl 4.38g 
1% NA Deoxycholate 5g 
1% Triton X-100 5mL 
5mM EDTA 0.93g 
0.1% SDS 0.5g 
 
Note.  Dissolve Tris base in 400mL diH2O, adjust pH to 8.0 using HCl, add remaining 
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Measurement of Circulating Biomarkers  
 To measure changes in serum hormone concentrations, serum analysis was 
conducted. ELISA assay kits were purchased from Crystal Chem for mouse insulin 
(90080), adiponectin (80569), and leptin (90030). No changes to the manufacturers 
guidelines were made.  
Gene Expression Profiles 
 For WAT, ~100mg frozen tissue was added to an RNAse-DNAse free tube 
containing ceramic beads. 1mL of Trizol Reaget (Fisher Scientific) was added and the 
tissue was homogenized using a VWR Mini-Bead mill at speed 5 for 30 seconds. 
Samples are incubated at room temperature for 5 minutes to allow complete 
dissociation of nucleoproteins. The homogenate is then centrifuged at 12,000g for 10 
minutes at 4°C. Avoiding the disturbance of the fat layer, 600µL of the RNA solution 
is removed and placed in a fresh tube. Then, 200µL of chloroform is added to each 
tube, shaken vigorously for 15 seconds, and incubated at room temperature for 3 
minutes. To separate the layers, the tubes are centrifuged at 12,000g for 15 minutes at  
4°C . 300µL of the upper, colorless layer is removed and placed in a fresh tube. An 
equal amount of 95-100% ethanol is added and mixed by pipetting. Then RNA 
isolation is carried out using the Zymo Direct-zol RNA Mini Prep kit (Genesee 
Scientific, 11-330). For BAT, ~100mg frozen tissue is added to an RNAse-DNAse 
free tube containing ceramic beads. 600µL of Trizol reagent is added and the tissue is 
homogenized using a VWR Mini-Bead Mill on speed 5 for 30 seconds. The tubes are 
centrifuged at 13,500rpm for 5 minutes at 4°C. 350µL of supernatant is transferred to 
a fresh tube, and an equal volume of 100% ethanol is added and mixed by pipetting. 
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Then RNA isolation is carried out using the Zymo Direct-zol RNA Mini Prep kit 
(Genesee Scientific, 11-330). 
RNA concentration and quality are measured using a Biotek Take3 plate and 
Cytation5 Imager. The RNA concentration is adjusted using RNA-ase/DNA-ase free 
water, and 1µg RNA is added to iScript Reverse Transcriptase mix. cDNA is 
synthesized, diluted to a total volume of 50µL per sample. For qPCR, 25ng of 
template cDNA, 500nM of forward and reverse primer, and EvaGreenER buffer are 
used. Results were analyzed using the methods described by Livak & Schmittgen 
(2001). qPCR primer sequences are listed in table 7. 
Adipose Histology 
A small piece of fresh adipose tissue was carefully cut from the middle of the 
depot, avoiding jagged edges when cutting. The tissue was fixed in 10% formalin at 
room temperature overnight. The following day tissue was washed three times in 70% 
ethanol to remove excess formalin and stored in 70% ethanol at 4°C until pickup. 
Embedding in paraffin wax, slicing, H&E staining, and slide imaging were done by 
Histoserv, Inc. Representative images were taken of each slide and cropped to be 















Oligonucleotide sequences for qPCR primers 
Gene Forward Reverse 
Bcat2 5’-CAGCCACACTAGGACAGGTCT-3’ 5’-CAGCCTTGTTATTCCACTCCAC-3’ 
Bckdk 5’-ACATCAGCCACCGATACACAC-3’ 5’-GAGGCGAACTGAGGGCTTC-3’ 
Cyclo 5’-GGAGATGGCACAGGAGGAA-3’ 5’-GCCCGTAGTGCTTCAGCTT-3’ 
Pgc1α 5’-AGACAAATGTGCTTCCAAAAAGAA-3’ 5’-GAAGAGATAAAGTTGTTGGTTTGGC-3’ 
PparY 5’-CTCTGGGAGATTCTCCTGTTGA-3’ 5’-GGTGGGCCAGAATGGCATCT-3’ 
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GC-MS Metabolomics 
Frozen adipose tissue (~100mg for WAT, ~10mg for BAT) was added to a tube 
containing 13C labeled stable isotope standards (Tables 8, 9, and 10), water, 2:1 
chloroform: methanol, and zirconium oxide beads. The tissue was homogenized for 30 
seconds using a mini bead mill (VWR) on speed 5. A one hour extraction was 
performed on ice, vigorously shaking the samples every 10 minutes. To separate the 
layers, the samples were spun at 3,000rpm for 5 minutes at 4°C. The upper aqueous 
layer was removed and dried under nitrogen. To generate oximes, 2% methoxyamine 
hydrochloride in pyridine was added and the samples microwaved at 350W for 90 
seconds. Then the metabolites were converted to TBDMS derivatives by heating at 
90°C for one hour. Metabolites were run on GC-MS (Agilent): separation was achieved 
using a HP-5MS UI column and detection used single ion monitoring. 
Statistical Analysis 
 
 This study utilized a completely randomized design, with the possibility of a 
cage effect. Mean and standard error of the means (SEM) were calculated for each data 
set. Significance was calculated using one-way ANOVA or an unpaired t-test. 
Comparisons were made only between the means of LF vs LB and HF vs HB. 
Significance was accepted at a p-value less than or equal to 0.05. Graph generation and 
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Table 8 
Stable Isotope Labeled Internal Standard for Organic Acids 
 
Note. Stable isotope labeled internal standard stock concentrations of organic acids 

















(µg) OA in 
(25 uL) IS 
Sodium Pyruvate (13C3) 113.02 257.0 0.726 
Sodium Lactate (3,3,3-D3) 115.06 251.2 0.723 
Citric Acid (2,2,4,4-D4) 196.15 252.4 1.237 
α -Ketoglutaric Acid (3,3,4,4-D4) 150.12 256.8 0.964 
Succinic Acid (D6) 124.13 257.4 0.799 
Fumaric Acid (D4) 120.1 261.4 0.785 
Malic Acid (2,3,3-D3) 137.11 257.1 0.881 
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Table 9 







(µg) AA in 
IS (25 uL) 
L-Alanine (13C3, 15N) 89.09 248 0.55 
L-Glycine (13C2, 15N) 75.07 248 0.47 
L-Valine (13C5, 15N) 117.1 247 0.72 
L-Leucine (13C6, 15N) 131.2 248 0.81 
L-Isoleucine (13C6, 15N) 131.2 248 0.81 
L-Proline (13C5, 15N)  115.1 245 0.70 
L-Methionine (13C5, 15N) 149.2 248 0.93 
L-Serine (13C3, 15N) 105.09 247 0.65 
L-Threonine (13C4, 15N) 119.1 245 0.73 
L-Phenylalanine (13C9, 15N) 165.2 245 1.01 
L-Aspartic Acid (13C4, 15N) 133.1 245 0.82 
L-Glutamic Acid (13C5, 15N) 147.1 250 0.92 
L-Lysine:2HCL (13C6, 15N2) 146.2 247 0.90 
L-Histidine:HCL:H2O (13C6, 15N3) 155.2 250 0.97 
L-Tyrosine (13C9, 15N)  181.2 249 1.13 
 
Note. Stable isotope labeled internal standard stock concentrations of amino acids 
which were spiked into each sample for the determination of metabolite concentrations.  















KA in IS (15uL) 
α -Ketoisocaproic Acid (13C6) 158.08 52.6 0.125 
Sodium 2-Keto-3-Methyl-
Pentanoate (13C6) 
158.08 50.7 0.12 
α -Ketoisovaleric Acid (13C5) 143.06 51 0.109 
 
Note. Stable isotope labeled internal standard stock concentrations of keto acids which 
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Chapter 4:  Results 
 
Objective 1:The Impact of BCAAS on Adipose Tissue Morphology and Development 
 First, to study the impact of BCAA supplementation on adipose tissue 
morphology and development, we began by characterizing the phenotypes of the mice 
reared on the four different diets. After 12 weeks on the custome diets, the low-fat 
BCAA supplemented group (LB) had significantly higher body weights compared to 
their control counterparts (Figure 7A). There was no difference in body weights 
between LF and LB after 34 weeks on diet. High-fat (HF) fed animals showed no 
differences from their BCAA supplemented counterparts (HB) in body weights after 
12 or 24 weeks on the custom diets (Figure 7B).  
 Perigonadal adipose tissue weights were significantly higher in the 12 week 
BCAA supplemented group, LB compared to LF (Figure 7C). Conversely, after 34 
weeks of BCAA supplementation, fasted perigonadal adipose weights in the LB mice 
were lower than their LF counterparts (Figure 7C).  However, 24 weeks of BCAA 
supplementation on a high-fat background resulted in significantly higher perigonadal 
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Figure 7: A) Fed and fasted body weights of LF and LB groups after 12 and 34 weeks 
on their respective diets, B) Fed and fasted body weights of HF and HB groups after 
12 and 24 weeks on their respective diets, C) Fed and  fasted perigonadal WAT weights 
after 12 weeks on the diets and fasted perigonadal WAT weights in LF and LB groups 
after 34 weeks on the diets D) Fed and fasted perigonadal WAT weights of HF and HB 
groups after 12 and 24 weeks on diet. Data is presented as means ± standard error of 
means (SEM). n= 6-10 per treatment group. Differences in the means indicated by *p 
< 0.05, **p<0.01, ***p < 0.001 
 
A B   
C D 
  37 
 To determine if BCAA supplementation impacted patterns of lipid storage, six 
adipose depots were collected from mice on diet for 12 weeks (Figure 8A) and weighed 
(Figure 8B). These depots represented four adipose depot types: subcutaneous 
(interscapular and inguinal WAT), visceral (perigonadal and mesenteric WAT), 
intermuscular (popliteal WAT), and BAT (interscapular BAT). Mice supplemented 
with BCAAs on a high-fat background had significantly lower perigonadal, mesenteric, 
and popliteal WAT and lower interscapular BAT (Figure 8B) than  the HF control mice. 
The adipose tissue weights between LF and LB groups were not statistically different 
from each other. 
Over the course of dietary feeding, the animals feed intake and body weights 
were measured weekly. During 12 weeks on diet, the LB group maintained higher body 
weights (Figure 9E) compared to LF. After 34 weeks on diet, supplemented animals 
consumed more feed and kilo-calories on average per day (Figure 10A and B) 
compared to their LF counterparts. In the high-fat groups, HF caloric intake is higher 
than HB at 12 weeks (Figure 11B). Extension of the time on the custom diets to 24 
weeks exacerbated differences in caloric intake and revealed decreased feed intake in 













Figure 8: A) Image depicting the 6 murine adipose depots weighed. inscBAT -
interscapular BAT, inscWAT - interscapular WAT, mWAT - mesenteric WAT, 
ingWAT - inguinal WAT, pWAT - popliteal WAT, pgWAT - perigonadal WAT B) 
Weight (g) of adipose depots. Data is presented as means ± SEM. n= 6 per treatment 
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Figure 9: LF and LB feed intake and body weights over 12 weeks of dietary 
intervention. A) Average grams of feed consumed per mouse per day, B) Average kcal 
consumed per mouse per day, C) Average grams of feed consumed per mouse per day 
over 12 weeks on custom diets,  D) Average kcal consumed per mouse per day over 12 
weeks on custom diets, E) Body weight over 12 weeks on custom diets. Data is 
presented as means ± SEM. n=10 per treatment group. 
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Figure 10: LF and LB feed intake and body weights over 34 weeks of dietary 
intervention. A) Average grams of feed consumed per mouse per day, B) Average kcal 
consumed per mouse per day, C) Average grams of feed consumed per mouse per day 
over 34 weeks on custom diets,  D) Average kcal consumed per mouse per day over 34 
weeks on custom diets, E) Body weight over 34 weeks on custom diets. Data is 
presented as means ± SEM. n=35 per treatment group. Differences in the means 









Figure 11: HF and HB feed intake and body weights over 12 weeks of dietary 
intervention. A) Average grams of feed consumed per mouse per day, B) Average kcal 
consumed per mouse per day, C) Average grams of feed consumed per mouse per day 
over 12 weeks on custom diets,  D) Average kcal consumed per mouse per day over 12 
weeks on custom diets, E) Body weight over 12 weeks on custom diets. Data is 
presented as means ± SEM. n=10 per treatment group. Differences in the means 
indicated by **p < 0.01. 




Figure 12: HF and HB feed intake and body weights over 24 weeks of dietary 
intervention. A) Average grams of feed consumed per mouse per day, B) Average kcal 
consumed per mouse per day, C) Average grams of feed consumed per mouse per day 
over 24 weeks on custom diets,  D) Average kcal consumed per mouse per day over 24 
weeks on custom diets, E) Body weight over 24 weeks on custom diets. Data is 
presented as means ± SEM. n=23 per treatment group. Differences in the means 
indicated by **p < 0.01, ***p<0.001 
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 To determine whether these animals are insulin resistant, serum insulin c-
peptide were measured using a ELISA assays (Crystal Chem). After 12 weeks on diet 
and following fasting, the HF and HB animals demonstrate a trend of higher circulating 
insulin and c-peptide compared to the low-fat groups (Table 12). Insulin levels in the 
HF and HB groups after 24 weeks of supplementation are elevated even further. LB 
animals that were supplemented for 34 weeks had significantly lower insulin levels 
after fasting than LF.  
Adiponectin, a hormone that has been recognized to positively impact insulin 
sensitivity, was not significantly different between the four groups after 12 weeks of 
dietary intervention (Table 12).  
Leptin is a starvation hormone that, when its concentration falls below a certain 
threshold, signals the brain to stimulate more feed intake. Leptin also is closely related 
to insulin resistance. After 12 weeks on the custom diets, fed HF mice demonstrated 
significantly higher leptin levels than their supplemented counterparts (Table 12).  
Morphological differences in adipose tissue were observed by histological 
analysis. In the WAT of mice on the custom diets for 12 weeks, LB animals appeared 
to have larger white adipocytes than the LF (Figure 13A). The opposite trend is seen in 
HB, where smaller adipocytes are present compared to HF (Figure 13B). In BAT, even 
stronger differences in lipid accumulation and adipose expansion are noted. Both the 
LB and HB groups demonstrate reduced lipid droplet size and number compared to 
their control diet counterparts (Figure 14A and B).  
 
 







Serum Insulin and C-Peptide Analysis  
Insulin (ng/mL) LF LB HF HB 
12wks, Fed 0.46 ± 0.12 0.52 ± 0.08 0.48 ± 0.08 0.41 ± 0.06 
12wks, Fasted 0.12 ± 0.01 0.14 ± 0.02 0.29 ± 0.07 0.22 ± 0.05 
34/24wks, Fed -- -- 10.37 ± 1.92 6.49 ± 1.54 
34/24wks, Fasted 0.28 ± 0.04a 0.19 ± 0.02a 1.07 ± 0.12 2.26 ± 0.56 
C-Peptide (ng/mL)     
12wks, Fed 0.49 ± 0.05 0.58 ± 0.09 0.62 ± 0.11 0.52 ± 0.08 
12wks, Fasted 0.17 ± 0.05 0.16 ± 0.04  0.31 ± 0.09 0.29 ±0.05 
 
Note. Serum insulin and C-peptide profile of LF and LB mice after 12 and 34 weeks of 
supplementation and HF and HB mice after 12 and 24 weeks of supplementation. Data 
is presented as means ± SEM. n= 6 per treatment group. Results with the same 
superscript letter are statistically significant from each other (p < 0.05). 
 












Serum Hormone Analysis 
Serum Hormone LF LB HF HB 
Adiponectin (μg/mL, fed) 7.33 ± 0.37 6.6 ± 0.46 5.92 ± 0.22 5.59 ± 0.28 
Leptin (ng/mL, fed) 6.03 ± 0.81 6.03 ± 2.26 15.07 ± 3.35b 5.04 ± 1.83b 
 
Note. Serum adiponectin and leptin concentrations for mice on diet for 12 weeks and 
in the fed condition. Data is presented as means ± SEM. n= 6 per treatment group. 








Figure 13: Perigonadal WAT from mice on custom diets for 12 weeks and in the fed 
condition. Tissue was stained using H&E and imaged at 5x magnification A) LF and 
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Figure 14: Interscapular BAT from mice on custom diets for 12 weeks and in the fed 
condition. Tissue was stained using H&E and imaged at 10x magnification A) LF and 
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Objective 2: BCAA Degradation and Mitochondrial Function 
  
 To determine whether BCAA degradation rates were impacted by BCAA 
supplementation, we first looked at amino and keto acid concentrations in the 
perigonadal WAT  of mice on custom diets for 12 weeks and in the fed condition. In 
the LB group, all of the BCAAs and their respective keto acids were significantly 
higher than LF (Figure 15A and C). While not all the measurements in the HF and HB 
animals were significant, the trends were the same as the low-fat group comparisons 
(Figure 15B and D). These trends of higher BCAAs and keto acids are a promising 
indicator that there is more BCAA degradation occurring in the supplemented tissues.  
 To substantiate the GC-MS data and further study the BCAA degradation 
pathway, three genes were measured for their relative expression using qPCR. 
Branched-chain aminotransferase (Bcat2) performs the first step of BCAA degradation. 
Branched chain keto acid dehydrogenase kinase (Bckdk) inhibits the activity of the 
second BCAA degradation enzyme, BCKDH. The third gene, peroxisome proliferator 
activated receptor-gamma (Pparγ), upregulates BCAA degradation when activated. For 
all four groups, there were no significant differences in gene expression (Figure 16A 











          
                       
                                             
Figure 15: Targeted metabolomics of amino acids and keto acids in perigonadal WAT 
from mice on custom diets for 12 weeks and in the fed condition A) Amount of amino 
acids in WAT of LF and LB animals B) Amount of amino acids in WAT of HF and 
HB animals C) Amount of keto acids in WAT of LF and LB animals D) Amount of 
keto acids in WAT of HF and HB animals. Data is presented as means ± SEM. n=6 per 











         
                                                         
Figure 16: Perigonadal WAT qPCR analysis of BCAA degradation gene expression 
of fed, 12 week supplemented animals. Data is expressed as fold change compared to 
the control diet (LF or HF) A) LF and LB gene expression B) HF and HB gene 
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BCAA degradation and mitochondrial function are closely linked 
characteristics of obesity, T2DM, and NAFLD. We wanted to study if BCAA 
supplementation would impact adipocyte mitochondrial function. To do this, we 
measured tri-carboxylic acid (TCA) cycle intermediates using GC-MS. In perigonadal 
WAT of mice on custom diets for 12 weeks and in the fed condition, all four groups 
showed no significant differences in TCA cycle intermediates (Figure 17A and B).  
 Protein expression of the electron transport chain complexes (OXPHOS) and 
cytochrome-C oxidase (COXIV) were measured by western blot analysis as another 
measure of mitochondrial function. There were no significant differences between LF 




















                 
                                                     
Figure 17: Targeted metabolomics of organic acids in perigonadal WAT of 12 mice 
on custom diets for 12 weeks and in the fed condition A) Amounts of organic acids in 
LF and LB groups B) Amounts of organic acids in HF and HB groups. Data is presented 
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Figure 18: Western blots of mitochondrial proteins associated with the electron 
transport chain expressed in perigonadal WAT of mice on custom diets for 12 weeks 
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Figure 19: Western blots of mitochondrial proteins associated with the electron 
transport chain expressed in perigonadal WAT of mice on custom diets for 12 weeks 
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The same battery of experiments were conducted in interscapular BAT to 
measure BCAA degradation and mitochondrial function. GC-MS analysis was 
conducted to measure amino acids in the interscapular BAT of animals on custom diets 
for 12 weeks. LB animals trended to have higher amino acids than LF (Figure 20A). 
The HB group had significantly more glutamate, valine, leucine, and isoleucine than 
HF (Figure 20B). The keto acids appeared higher in the LB group (Figure 20C), as well 
as in HB mice (Figure 20D) compared to their control counterparts.  
For gene expression after 12 weeks on custom diets, we used qPCR to measure 
the interscapular BAT gene expression of Bcat2, Pgc1α, and Ucp1. Bcat2 is the first 
enzyme in the BCAA degradation pathway. Pgc1α is a transcription co-activator that 
induces mitochondrial biogenesis and is activated during cold stress. Lastly, Ucp1 is 
the thermogenesis protein that utilizes lipids and BCAAs for heat production. There 
were no significant differences in gene expression between the low-fat groups (Figure 
21A) or high-fat groups (Figure 21B). 
TCA cycle intermediates were measured by GC-MS in interscapular BAT of 
mice on custom diets for 12 weeks. LB animals had significantly higher pyruvate and 
trended to have higher amounts of intermediates than LF (Figure 22A). HF and HB 
animals were not statistically different from each other (Figure 22B).  
 
 




                                                      
 
Figure 20: Targeted metabolomics of amino acids and keto acids in interscapular  BAT 
from mice on custom diets for 12 weeks and in the fed condition. A) Amount of amino 
acids in BAT of LF and LB animals, B) Amount of amino acids in BAT of HF and HB 
animals, C) Amount of keto acids in BAT of LF and LB animals, D) Amount of keto 
acids in BAT of HF and HB animals. Data is presented as means ± SEM. n=6 per 
treatment group. Results were considered significant at *p < 0.05 
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Figure 21: Interscapular BAT qPCR analysis of BCAA degradation and thermogenesis 
gene expression of mice on custom diets for 12 weeks and in the fed condition. A) LF 
and LB gene expression B) HF and HB gene expression. Data is presented as means ± 











          
                                                               
Figure 22: Targeted metabolomics of organic acids in interscapular BAT from mice 
on custom diets for 12 weeks and in the fed condition. A) Amounts of organic acids in 
LF and LB groups B) Amounts of organic acids in HF and HB groups. Data is presented 
as means ± SEM. n=5-6 per treatment group. Results were considered significant at 
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Figure 23: Western blots of mitochondrial proteins associated with the electron 
transport chain expressed in interscapular BAT of mice on LF and LB diets for 12 
weeks and in the fed condition. n=6 per group. 
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Figure 24: Western blots of mitochondrial proteins associated with the electron 
transport chain expressed in interscapular BAT of mice on HF and HB diets for 12 
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Objective 3: Impact of BCAAs on Lipolysis  
 We measured higher serum non-esterified free fatty acids (NEFA) in the 34 
week LB group compared to LF (Figure 25A), while no difference in serum NEFA was 
measured between the 24 week HF and HB groups (Figure 25B). To determine if the 
elevated circulating free fatty acids in the LB group were due to increased adipose 
tissue lipolysis, we performed an in vitro lipolysis assay using perigonadal WAT 
explants. Explants were incubated in a media with or without 5µM isoproterenol at 
37°C and 5% CO2.  
Lipolysis releases both fatty acids and glycerol, so both were measured in the 
lipolysis assay media. The LB group showed trends of increased basal fatty acid release 
(Figure 25A). Isoproterenol was very effective at inducing lipolysis and increased fatty 
acid release, however there were no differences between the LF and LB groups in the 
stimulated condition. The LF group had a significantly higher basal to stimulated fold 
change compared to LB. There were no significant differences in HF and HB fatty acid 
release (Figure 25B). To substantiate this data, glycerol in the media was also 
measured. The basal glycerol release in the LB group is significantly higher than LF, 
which agrees with the fatty acid trend. In the HB group, glycerol release in the basal 
















             
                                                                
Figure 25: Serum non-esterified fatty acids (NEFA) in A) 34 week LF and LB groups  
and B) 24 week HF and HB groups. Data is presented as means ± SEM. n=8-10 per 
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Figure 26: In vitro lipolysis assay results from fasted, LF and LB mice on custom diets 
for 34 weeks and fasted, HF and HB mice on custom diets for 24 weeks. A) LF and LB 
concentrations of free fatty acids released in lipolysis assay media B) HF and HB 
concentrations of free fatty acids released in lipolysis assay media C) LF and LB 
glycerol release into lipolysis assay media D) HF and HB glycerol release into lipolysis 
assay media. Data is presented as means ± SEM. n=8-10 per treatment group. Results 
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 If our hypothesis is that BCAA supplementation will induce lipolysis, then 
directly treating the adipose explants with BCAAs should also induce lipolysis. For this 
set of experiments, perigonadal WAT explants from fasted mice on diets for 12 week 
were incubated in a media with 500µM and 1mM BCAAs. Consistently across all four 
groups, higher BCAA concentrations in the media induced increased fatty acid release 
into the media (Figure 27). To further support this trend, another lipolysis assay was 
performed on normal, chow fed mice. For this experiment, perigonadal WAT was 
incubated in basal and 2.5µM ISP media with 50µM, 500µM, 1mM, or 2.5mM BCAAs. 
This was to test if BCAAs could sustain a higher lipolytic rate following stimulation. 
While the results are inconclusive, the trend of higher basal to stimulated fold changes 
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Figure 27: In vitro lipolysis assay free fatty acid release from fasted, 12 week 
supplemented mice treated with 500µM and 1mM BCAAs. Data is presented as means 
± SEM. n=8-10 per treatment group. 
 
    
Figure 28: In vitro lipolysis assay fatty acid release of pgWAT explants from normal, 
chow-fed mice treated with 50µM, 500µM, 1mM, and 2.5 mM BCAAs. Data is 
presented as means ± SEM. n=6 per treatment group. 
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Chapter 5:  Discussion 
 
Impacts of BCAA Supplementation on Adipose Tissue Morphology and Development 
 
 Supplementation of BCAAs resulted in changes to the body weights and 
adipose tissue phenotype. After 12 weeks on diet, the LB mice had heavier body and 
perigonadal WAT weights compared to their LF controls (Figure 7A and C). Consistent 
with our observations, Ribeiro et al. demonstrates a correlation between high 
circulating BCAAs and increased adipose and body weight in mice (2019). Given that 
these are young, growing mice, supplementing BCAAs could also have preferentially 
impacted their growth rate and protein synthesis. The HF and HB animals, on the other 
hand, maintained similar body weights and perigonadal WAT weights after 12 weeks 
on the custom diets. However after 24 weeks on these diets, HB animals had  
significantly higher perigonadal WAT weights following an overnight fast (Figure 7D). 
This was contrary to our expectations that during the feeding to fasting transition, the 
adipose weight will decrease as a consequence to high rates of lipolysis. The higher 
perigonadal adipose tissue weights after fasting in HB mice highlights the differential 
regulation of the adipose tissue phenotype following BCAA supplementation and 
warrants further investigation. 
 The dynamic interaction between BCAAs and adipose depot weights was futher 
illustrated by the observations that the HB animals maintained on custom diets for 12 
weeks, under fed conditions, mantained significantly lower visceral, BAT, and 
intermuscular adipose weights than the HF mice. No significant difference was 
  67 
measured in subcutaneous depot weights between the HF and HB mice (Figure 8B). 
The size of visceral adipose depots is correlated to metabolic health, as individuals with 
large visceral adipose depots are thought to be more metabolically unhealthy. On the 
other hand, those with large subcutaneous depots tend to be more insulin sensitive and 
have a decreased risk of developing metabolic diseases including T2DM (Mittal, 2019).  
After BCAA supplementation, not only is the overall adipose tissue weight reduced in 
HB animals, but there appears to be preferential lipid storage away from the visceral 
adipose tissue depots. Comparing the relative visceral to subcutaneous adipose weights, 
this could be a mechanism by which BCAAs are protecting the BCAA supplemented 
mice from the progressive severity of metabolic disease.  
 Significant differences in feed intake was also observed following CAA 
supplementation. After 34 weeks of dietary BCAA supplementation, LB animals 
consumed significantly more food on both grams and kilo-calories per day basis 
(Figure 10A and B). This was in spite of the fact that the LB mice adipose weights were 
significantly lower than LF (Figure 7A). These results could indicate that the LB 
animals have higher metabolic rates and a higher efficiency to divert these calories 
towards oxidation as opposed to storage as lipids.  
 In the HF and HB groups, differences in average kcal of feed consumed after 
12 weeks on the diets was significantly different, but no changes in the amount of feed 
consumed were observed (Figure 11B). This is likely because of the initial differences 
in calorie density between the HF and HB diets (Table 1). Since the HB diet inherently 
contains less kcal per gram, consuming the same grams of feed would equate to the HB 
animals obtaining less calories. After 24 weeks on diet, however, we see not only less 
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calories being consumed by HB animals, but also significantly lower feed intake 
(Figure 12A and B). This is no longer a matter of calorie density of the diets, but a 
significant reduction in the amount of food the HB mice are consuming. This trend in 
food intake is interesting considering the results that the perigonadal adipose tissue 
weights of the HB mice were significantly higher after fasting. These trends comparing 
the HF and HB mice are also opposite of the trend observed in the 34 week LF and LB 
mice. In the HB group, these mice consume significantly less feed, but maintain larger 
perigonadal WAT weight. It is widely understood that altering protein content in a diet 
impacts appetite. Generally, low dietary protein induces hyperphagia (Laeger et al., 
2014) while high amounts of protein satiate more readily (Bensaïd et al., 2003).  While 
both LB and HB animals are supplemented with higher levels of BCAAs, our results 
suggest that insulin resistance in the HB animals can differentially impact food intake 
and adipose tissue accretion. 
 In the context of normal physiology, insulin levels should readily decrease in 
response to fasting and rise following feeding. During insulin resistance, fasted levels 
of insulin will remain high due to the system being unable to efficiently clear 
circulating glucose and would be even higher during feeding due to insulin resistance. 
There were no significant differences in the fed insulin and c-peptide levels between 
the four groups of mice after 12 weeks on custom diets (Table 11). In the fasted 
condition, however, it is noted that the HF and HB groups insulin concentrations begin 
to remain elevated compared to the low-fat groups, indicating that these animals may 
be in the early stages of developing insulin resistance. The measured serum c-peptide 
concentrations agree with this observation. Extending the dietary treatments to 24 
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weeks resulted in a significant increase in serum insulin levels in both HF and HB 
groups compared to the LF and LB counterparts. In the HF and HB groups, serum 
insulin concentrations are very high in the fed condition compared to the 12 week 
values. This shows these animals require higher amounts of insulin to maintain glucose 
homeostasis. Once fasted, the insulin levels do decrease, but not to the extent of the 12 
week animals. It is clear that these HF and HB animals are insulin resistant after 24 
weeks of high fat diet feeding and this may be the reason for the opposing trends in 
feed intake and adipose weight between the LB and HB animals. This indicates that 
BCAA supplementation impacts physiology differently depending on the presence and 
severity of insulin resistance. 
 Leptin is an appetite hormone produced by adipose tissue. When adipose stores 
are sufficient, leptin levels rise, signaling the hypothalamus to limit feed intake. During 
starvation, when lipid stores become depleted, leptin levels fall and induce feeding. 
Also related to insulin resistance, leptin resistance is present during obesity due to the 
chronic excess nutrient intake (Kelesidis et al., 2010). Although no differences in 
adiponectin were measured, serum leptin showed some interesting trends (Table 12). 
In the 12 week HF group circulating leptin levels were significantly higher than HB 
(Table 12). This indicates the HF animals are developing leptin resistance while the 
BCAA supplemented animals are maintaining normal leptin levels, similar to the low-
fat fed groups. BCAAs could be impacting leptin regulation by some unknown 
mechanism, and preventing early stages of leptin resistance induced by high-fat 
feeding.  
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 This leptin data does not agree with the measured feed intake, however. If HB 
animals have lower leptin levels, that should trigger increased feed intake. At 12 weeks 
of dietary intervention, we see no differences in feed intake between HF and HB 
(Figure11A). It appears that these differences in leptin are not the cause for the changes 
in feed intake. There is likely independent mechanisms by which BCAAs are impacting 
leptin release and feed intake. 
 Comparing the perigonadal WAT histology from the fed, 12 week groups, there 
are slight differences in morphology and adipocyte size between the BCAA 
supplemented groups and their control counterparts. Adipocyte size appears slightly 
larger in the LB group compared to LF, however this agrees with the adipose weight 
(Figure 7C). Similarly, smaller adipocytes are present in the HB group compared to its 
HF counterpart, and perigonadal adipose weight was lower in the HB group during the 
fed condition (Figure 7D) 
In the BAT histology, there are significant differences in the accumulation of 
lipids (Figures 8 and 14). Comparing LF and LB, LB animals have less lipid 
accumulation and smaller, fewer lipid droplets even though they maintained higher 
BAT weight. Further, HB animals have BAT with lipid droplet sizes that are 
comparable to the LF and LB groups, compared to higher lipid accumulation in BAT 
from HF fed mice. The reduction in lipid accumulation, especially in the HB group, is 
an interesting result, especially considering the recent push to pursue BAT specific 
therapies for the treatment of T2DM and obesity. If BCAA supplemented tissue has a 
greater propensity to oxidize lipids, leading to reduced lipid accumulation, that could 
have implications for the treatment of metabolic diseases.  
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From this data, it is clear that BCAAs are having an impact on adipose tissue 
development and morphology. Supplementation of dietary BCAAs impacts adipose 
tissue weights, preferential lipid storage, feed intake, circulating serum leptin 
concentrations, and adipose tissue morphology. Because of the differences in 
perigonadal WAT weight and feed intake in the 34 week LB and 24 week HB mice, it 
is clear that BCAAs impart different effects on normal and insulin resistant systems. 
However in the 12 week HF and HB animals, where insulin resistance was in its early 
stages, BCAAs appear to be protecting the HB mice from metabolic disease 
progression by reducing visceral depot weights and circulating leptin levels. 
BCAA Degradation and Mitochondrial Function 
 Impairment of BCAA degradation network is a hall mark of diseases like obesity, 
T2DM, and NAFLD, and is believed to contribute to the increased circulating BCAA levels 
during these diseases (Zhang et al., 2016). Perigonadal WAT from fed, 12 week BCAA 
supplemented mice showed increases in the amount of BCAAs and their respective keto 
acids (Figure 15). This significant increase in BCAAs is proof that the dietary BCAAs are 
being taken up by the tissues and available to be utilized by the adipocytes. The levels of 
keto acids indicate BCAA degradation is readily occurring, and at a higher rate than in the 
control tissues.  BCAA degradation impairment has been linked to furthering the 
progression of metabolic diseases (Siddik & Shin, 2019). Dietary supplementation of 
BCAAs may protect high-fat diet impairment of BCAA degradation by upregulating the 
pathway, achieving prolonged BCAA catabolic efficiency compared to high-fat diet 
counterparts. 
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 To corroborate target metabolomics, the expression of three genes were 
measured: Bcat2, Bckdk, and Pparγ. Bcat2 is directly involved in the BCAA 
degradation pathway, Bckdk inhibits BCAA degradation, and Pparγ has been shown to 
regulate BCAA degradation (Blanchard et al., 2018). Although no significant 
differences in gene expression were measured (Figure 16), many studies have linked 
BCAAs to changes in gene expression (Heng et al., 2020; Liu et al., 2017). There has 
also been literature evidencing the down-regulation of BCAA degradation genes due 
to high-fat feeding (Haydar et al., 2018; Sjögren et al., 2020) Due to the chronic nature 
of the dietary supplementation, BCAAs may not impact gene expression after a 
prolonged period of time. A more acute dietary supplementation may be required to 
see these impacts or directly measuring protein expression and activity. 
 To study the impacts of BCAA supplementation on mitochondrial function, we 
used targeted metabolomics to measure TCA cycle intermediates. After 12 weeks on 
the custom diets, there were no significant differences in TCA intermediates between 
either LF and LB or HF and HB animals (Figure 17). Western blots measuring the 
electron transport chain proteins also showed no differences between the groups either 
(Figures 18 and 19). This data suggests that WAT mitochondrial function was not 
affected by BCAA supplementation. However, this data was using tissues from animals 
in fed condition so differences may be better seen using fasted animals or measuring 
the feeding to fasting transition.  
 For BAT, GC-MS measurements of amino and keto acids showed trends of 
increased amino and keto acids in the LB animals (Figure 20A and C). The HB group 
had significantly more glutamate (a BCAA degradation product), BCAAs, and keto 
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acids (Figure 20B and C). Again, these trends are promising indications that there is 
increased degradation occurring in the supplemented tissues. 
 Yoneshiro et al. has evidenced BCAAs being utilized as substrates by BAT 
during non-shivering thermogenesis (2019). For BAT qPCR, BCAA degradation and 
thermogenesis genes were measured. We again measured Bcat2, which is directly 
involved in BCAA degradation. We also measured Pgc1α and Ucp1 as thermogenic 
genes. Similar to WAT, there were no differences in gene expression between any of 
the groups (Figure 21). Once again, due to the chronic supplementation changes in gene 
expression may not be sustained for the full dietary supplementation.  
 Shifting our focus to mitochondrial function in BAT, LB animals had 
significantly more pyruvate and trended to have higher intermediates than their LF 
controls (Figure 22A). This could indicate higher TCA cycle flux, and may be related 
to the decreased lipid accumulation seen in the BAT histology (Figure 14). Western 
blots of mitochondrial electron transport chain proteins show no differences between 
the groups. Similar to WAT, this data suggests no impacts of BCAA supplementation 
on mitochondrial function, however the comparison of feeding to fasting may present 
some differences. 
 
Impacts of BCAA supplementation on Adipose Tissue Lipolysis 
 Extended supplementation of BCAAs for 34 weeks increased fasting serum 
NEFA levels in LB animals compared to LF (Figure 25A). BCAAs have recently been 
shown to impact lipolysis (Heng et al., 2020), and are known to impact molecular 
mediators of lipolysis including AMPK (Coughlan et al., 2013). To see if BCAA 
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supplementation increases circulating fatty acids through induction of the lipolysis 
pathway, an in vitro lipolysis assay was performed.   
 LB animals showed increased basal lipolysis rates through higher fatty acid and 
glycerol release (Figure 26A and C). This agrees with the serum NEFA measurements 
and indicates that BCAAs can induce lipolysis and are capable of impacting circulating 
FFA levels in the fasted condition. In the HF and HB mice, where insulin resistance is 
present, there are no differences in fatty acid release and reduced free glycerol into the 
incubation media (Figure 26B and D).  
 Next we tested if directly treating the adipose explants with BCAAs can induce 
lipolysis. Across all four groups of 12 week supplemented, fasted mice, the 1mM 
BCAA concentration consistently increased fatty acid release compared to the 500 µM 
(Figure 27), even though not in a statistically significant manner. This trend suggests 
that BCAAs can induce lipolysis in a concentration dependent manner. When we 
attempted this experiment again, with higher  BCAA concentrations and isoproterenol 
stimulation, the results were not as clear. However, a promising trend in the basal to 
stimulated fold change may suggest that the three highest BCAA concentrations 
positively impact WATs ability to upregulate lipolysis when stimulated with 
isoproterenol (Figure 28).  
 Across all experiments the trend remained fairly consistent that BCAA 
supplementation or treatment positively impacts lipolysis in normal animals. However 
when we attempted to demonstrate an increase in lipolysis following a BCAA 
concentration dependent manner the data was inconclusive.   
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Summary 
The conclusions of this study support our hypothesis that chronic, dietary 
supplementation of BCAAs does impact adipocyte function in WAT and BAT and 
that this effect was blunted by severe insulin resistance. Our result indicate that 
BCAAs positively impact adipocyte function in a normal animal, as well as 
protecting the system from the early stages of insulin resistance. However, once the 
disease has progressed in severity, it appears that BCAAs no longer impart these 
beneficial effects.  
Future Directions 
 This study leaves many questions unanswered, providing several avenues for 
future studies. 
1) There is  close relation of PPARγ, BCAA degradation, and adipocyte 
differentiation (Estrada-Alcalde et al., 2017; Green et al., 2016; Siersbaek et 
al., 2010). Would dietary supplementation of BCAAs impact adipocyte 
differentiation?  
2) The clear morphological differences in BAT require more study to understand 
the impacts BCAAs are having. Reduced lipid accumulation could be due to 
down regulation of lipid storage or upregulation of lipid oxidation, further 
studies could determine which pathway is responsible for this morphological 
difference.  
3) The differences in circulating leptin concentrations are another area of study. 
Leptin is released by adipose tissue, so BCAAs are regulating the ability of 
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adipose to release leptin. Additionally, what other factors could BCAAs be 
impacting to effect feed intake so significantly, as seen in this study? 
4) Finally, it is consistent that BCAAs are impacting lipolysis. The lipolytic 
pathway is well studied and understood, so measuring the protein and gene 
expression of the enzymes involved could elucidate a mechanism for this 
action.  
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